Novo Nordisk is diminishing the expense of Wegovy for specific individuals who pay independently.
Novo Nordisk is diminishing the expense of its weight reduction medication Wegovy to $499 each month for a few people who pay cash based through the maker’s new NovoCare Drug store. Eli Lilly executed a comparable action last month, diminishing the expense of its weight reduction medication Zepbound for specific individuals who pay cash based.
Novo Nordisk (NVO) is diminishing the expense of its well known weight reduction medication Wegovy for certain individuals who pay cash based. Wegovy will presently be accessible for $499 each month for all dosages through NovoCare Drug store, the maker’s new immediate to-understanding conveyance administration. This deal is for individuals who don’t have protection or whose business protection doesn’t take care of weight problems drugs. Already, individuals without protection paid $650 each month for the medication.
This action comes after the Food and drug administration concluded that the dynamic fixing in Wegovy and Novo Nordisk’s other weight reduction treatment, Ozempic, is as of now not viewed as being hard to find. Last month, rival Eli Lilly (LLY) additionally diminished the expense of its well known weight reduction medication Zepbound for individuals paying cash based after a comparable Food and drug administration administering.
Goldman Sachs experts have revealed that the weight reduction market, which is overwhelmed by Novo Nordisk and Eli Lilly, could reach $130 billion by 2030. Toncoin (TON) Value Forecast for March 26th
Novo Nordisk’s stock cost rose almost 4% on Tuesday, however has lost about a fourth of its worth in the beyond 12 months.
